Latest News

Tevogen Bio Expresses Gratitude as CEO is Named Recipient of Boy Scouts of America Distinguished Citizen Award

Tevogen Bio – May 11th, 2023

---

Tevogen Bio CSO to Discuss Investigational T Cell Therapy at NOLA Conference Focused on Long COVID and COVID-Related Cancer Risk, Alongside Leading Oncology Experts

Tevogen Bio – April 26th, 2023

---

Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform

Tevogen Bio – January 23rd, 2023

---

Tevogen Bio to Study its Investigational COVID-19 T Cell Therapy in Immunocompromised Patients Who are Unable to Benefit From Currently Available Prevention or Treatment Options

Tevogen Bio – December 7th, 2022

---

Tevogen Bio to Develop T Cell Therapies for Treatment of Epstein-Barr Virus Related Cancers and Multiple Sclerosis

Tevogen Bio – December 1st, 2022

---

Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID

Tevogen Bio – November 22nd, 2022

---

Tevogen Bio CEO Dr. Ryan Saadi and Chief Scientific Officer Dr. Neal Flomenberg share White House concerns about emerging COVID-19 variants and their impact on immunocompromised patients, and express the company’s commitment to accelerate development of its investigational COVID-19 therapy

Tevogen Bio – October 27th, 2022

---

Tevogen Bio Expresses Gratitude for 2023 Nobel Peace Prize Nomination of the Company and its Founding CEO Ryan Saadi in Recognition of its Novel Business Model to Alleviate Health Inequality

Tevogen Bio – October 12th, 2022

---

Warren-based biotechnology company Tevogen Bio, CEO nominated for 2023 Nobel Peace Prize

ROI-NJ – October 6th, 2022

---

Tevogen Bio Appoints Esteemed Global Safety Management Expert Victor Sordillo to its Corporate Advisory Board

Tevogen Bio – August 31st, 2022

---

Tevogen Bio Appoints Three Prominent Healthcare Leaders to its Board of Directors

Tevogen Bio – August 17th, 2022

---

Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment in Proof-of-Concept Clinical Trial of T cell Therapy for Elderly or High-Risk COVID-19 Patients

Tevogen Bio – August 1st, 2022

---

Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D

Tevogen Bio – July 7th, 2022

---

Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology

Tevogen Bio – June 30th, 2022

---

Tevogen Bio Appoints Distinguished Clinician and Former Matheny President and CEO, Dr. Kendell R. Sprott, to Corporate Advisory Board

Tevogen Bio – June 23rd, 2022

---

Ryan Saadi’s Commencement Speech at Washington University of Science and Technology

Tevogen Bio – June 21st, 2022

---

Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients

Tevogen Bio – June 7th, 2022

---

Tevogen Bio Expands Research and Development Capacity at CIC Philadelphia to Accommodate its Expanding Product Portfolio

Tevogen Bio – May 3rd, 2022

---

Tevogen Bio Expands Executive Leadership Team to Accelerate Operational Growth and Commercial Readiness

Tevogen Bio – April 5th, 2022

---

Tevogen Bio™ Appoints Prominent Industry Leader Susan Podlogar to the Company’s Corporate Advisory Board

Tevogen Bio – March 2nd, 2022

---

Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations

Tevogen Bio – February 7th, 2022

---

Tevogen Bio Announces Positive Safety Data from Second Cohort in Ongoing Proof-of-Concept Clinical Trial of TVGN-489, its Investigational T cell Therapy for Treatment of COVID-19 in High-Risk Patients

Tevogen Bio – February 3rd, 2022

---

SPH Dean’s next venture to drive down treatment costs

Yale Daily News – January 26th, 2022

---

Tevogen Bio to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis

Tevogen Bio – January 20th, 2022

---

Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy

Tevogen Bio – January 12th, 2022

---

Tevogen Bio Appoints Yale Public Health Dean Dr. Sten H. Vermund, Preeminent Global Expert in COVID-19 and Infectious Disease Epidemiology, to its Innovation and Public Health Advisory Council

Tevogen Bio – January 5th, 2022

---

Tevogen Bio Reinforces IP Portfolio With Additional US Patent for Its Investigational T Cell Therapy for Treatment of COVID-19

Businesswire – December 29th, 2021

---

Tevogen Bio Presents Data Detailing Immunologic Escape in SARS-CoV-2 Variants Underscoring Criticality of its T Cell Target Tuning Technology and Investigational COVID-19 therapy at ASH 2021

Businesswire – December 14th, 2021

---

Tevogen Bio Announces U.S. Patent and Trademark Office Has Granted Patent for Preparation of Tevogen’s SARS-CoV-2 Specific Allogeneic Cytotoxic T Lymphocytes (CTL) and Methods of Treatment Using Tevogen’s Investigational CTL Therapy for COVID-19

Businesswire – December 8th, 2021

---

Dr. Lindee Goh of Tapestry Networks and Jeffrey Feike, President and Chief Administrative Officer of Fort Loudoun Medical Center, Join Tevogen Bio’s Innovation and Public Health Advisory Council

Businesswire – December 6th, 2021

---

SHARED@Yale Roundtable Explores Health Care in the Era of COVID-19

Yale School of Public Health – December 6th, 2021

---

Tevogen Bio Announces its Investigational SARS-CoV-2 Specific T cell Therapy, TVGN-489, Is Not Affected by Omicron Variant Following Research Team Review of all Reported Mutations

Businesswire – December 2nd, 2021

---

FDA OK’s next phase for Jefferson University’s new COVID-19 treatment

6ABC News – November 29th, 2021

---

SHARED@Yale: Inaugural Roundtable on Post-COVID Health Care Announced

Yale School of Public Health – November 22nd, 2021

---

Tevogen Bio Announces First Cohort Dosed in Ongoing Proof of Concept Clinical Trial of TVGN-489, its Investigational T cell Immunotherapy Product for Treatment of COVID-19 in High-Risk Patients

Businesswire – November 16th, 2021

---

Tevogen Bio CEO Dr. Ryan Saadi Appointed to Yale School of Public Health Leadership Council

Businesswire – October 27th, 2021

---

A Pandemic Silver Lining: Why Now is our Opportunity to Disrupt the Flawed U.S. Health Care System

Yale School of Public Health – October 8th, 2021

---

Tevogen Bio Reaches Major Milestone in Commercial Manufacturing Readiness by Completing the Technology Transfer of its Investigational COVID-19 T Cell Therapy

Businesswire – September 9th, 2021

---

Tevogen Bio to Initiate Clinical Trial of its Investigational T Cell Therapy for COVID-19 at Thomas Jefferson University

Businesswire – September 1st, 2021

---

Tevogen Bio Revolutionizing Healthcare through an Innovative Public Health Centric Model

Pharma Tech Outlook – August 30th, 2021

---

Tevogen Bio Partners with Yale School of Public Health to Prepare Tomorrow’s Leaders in Regulatory Science

Businesswire – July 14th, 2021

---

Tevogen Bio Announces FDA Clearance of Investigational New Drug (IND) Application For its Cytotoxic T Cell Therapy for COVID-19

Businesswire – July 12th, 2021

---

Tevogen Bio’s TVGN-489, an Allogeneic SARS-CoV-2 Specific Cytotoxic T Cell Therapy, Demonstrates Strong Anti-Viral Activity in Preclinical Study, as Presented by Professor Neal Flomenberg of Thomas Jefferson University

Businesswire – May 11th, 2021

---

Tevogen Bio to Present Preclinical Data of TVGN-489, its Investigational Allogeneic Cytotoxic T Cell Therapy for COVID-19, at the 2021 Annual Meeting of American Association of Immunologists

Businesswire – April 12th, 2021

---

Tevogen CEO Ryan Saadi, MD, MPH, sat down with Cell & Gene Editor-In-Chief Erin Harris to discuss why T Cell therapy could be a potential game changer for COVID-19.

Cell & Gene – March 23rd, 2021

---

Tevogen Bio Announces Partnership With BioCentriq, New Jersey Innovation Institute’s Pioneering Cell and Gene Therapy Center, to Enhance Tevogen’s Development Capacity of Its Proprietary Targeted T Cell Therapy For COVID-19

Businesswire – March 15th, 2021

---

Tevogen Bio Secures Funding from Team of Doctors to Support Clinical Trials of Its Investigational Curative T Cell Therapy for COVID-19

Newswire – January 25th, 2021

---

Tevogen Bio Announces IND Submitted to FDA for Clinical Trials of T Cell Treatment for COVID-19

Newswire – October 14th, 2020

---

Dr. Flomenberg discusses T Cell therapy for COVID-19 with 6ABC News.

6ABC – August 20th, 2020

---

Tevogen Bio Announces Partnership With Preeminent Scientist Professor Neal Flomenberg, M.D., to Investigate Proprietary T-Cell Therapy for Treatment of COVID-19 & Influenza

Newswire – August 10th, 2020

---

Tevogen Bio Announces Steps Toward a Proprietary T Cell Therapy for Treatment of COVID-19 & Development of Bivalent Vaccine for COVID-19 & Influenza

Newswire – July 15th, 2020

Tevogen Corporate Office – Warren, New Jersey

Presenting the Future Research and Manufacturing Facility of Tevogen Bio

Tevogen Bio is pleased to finalize the design of its state-of-the-art, eco-friendly research and manufacturing facility to accommodate its anticipated growth. This planned facility will serve as the company’s central hub for research, manufacturing, and distribution. Congratulations to our team of visionary architects and lab engineers!

Social Media